Clinically significant prostate cancer is rarely missed by ablative procedures of the prostate in men with prostate specific antigen less than 4 ng/ml

Joshua J. Meeks, Alexandra C. Maschino, Kevin T. McVary, Jaspreet S. Sandhu*

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: Laser vaporization of the prostate is widely used to treat lower urinary tract symptoms. It may decrease the hospital cost and morbidity associated with transurethral resection of the prostate. However, prostate cancer may go undetected because tissue is not taken at laser vaporization. To our knowledge the rate of clinically significant prostate cancer missed by laser vaporization has not been assessed to date. We determined the rate of clinically significant prostate cancer detected by transurethral resection of the prostate compared to the estimated number of cancers missed by laser vaporization. Materials and Methods: A total of 74,505 men diagnosed with stage T1 prostate cancer between 2004 and 2006 were identified from the SEER (Surveillance, Epidemiology and End Results) program in the United States. The total number of laser vaporizations and transurethral resections were calculated based on Medicare claims for the same period. Clinically significant cancer was defined as that with a Gleason score of 7 or greater in men 40 to 75 years old. Results: If prostate specific antigen screening were used uniformly (excluding men with prostate specific antigen greater than 4 ng/ml), only 1 of 382 transurethral resections of the prostate would identify clinically significant prostate cancer for a total of 390 in the American population in 3 years. Based on Medicare reported laser vaporization use a total of only 163 clinically significant cancers would be missed in more than 60,000 procedures. Conclusions: The incidence of T1a and T1b prostate cancer remains low and few patients have clinically significant prostate cancer. When prostate specific antigen screening is used, the number of clinically significant tumors missed by ablative procedures is low (average of 0.26% of all procedures) and can be identified by prostate specific antigen screening.

Original languageEnglish (US)
Pages (from-to)111-115
Number of pages5
JournalJournal of Urology
Volume189
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Prostate-Specific Antigen
Laser Therapy
Prostate
Prostatic Neoplasms
Transurethral Resection of Prostate
Medicare
Neoplasms
SEER Program
Lower Urinary Tract Symptoms
Neoplasm Grading
Hospital Costs
Morbidity
Incidence
Population

Keywords

  • laser therapy
  • prostate
  • prostate-specific antigen
  • prostatic neoplasms
  • transurethral resection of prostate

ASJC Scopus subject areas

  • Urology

Cite this

@article{3f2d2db1cb10484c8267fd5fb8c02af3,
title = "Clinically significant prostate cancer is rarely missed by ablative procedures of the prostate in men with prostate specific antigen less than 4 ng/ml",
abstract = "Purpose: Laser vaporization of the prostate is widely used to treat lower urinary tract symptoms. It may decrease the hospital cost and morbidity associated with transurethral resection of the prostate. However, prostate cancer may go undetected because tissue is not taken at laser vaporization. To our knowledge the rate of clinically significant prostate cancer missed by laser vaporization has not been assessed to date. We determined the rate of clinically significant prostate cancer detected by transurethral resection of the prostate compared to the estimated number of cancers missed by laser vaporization. Materials and Methods: A total of 74,505 men diagnosed with stage T1 prostate cancer between 2004 and 2006 were identified from the SEER (Surveillance, Epidemiology and End Results) program in the United States. The total number of laser vaporizations and transurethral resections were calculated based on Medicare claims for the same period. Clinically significant cancer was defined as that with a Gleason score of 7 or greater in men 40 to 75 years old. Results: If prostate specific antigen screening were used uniformly (excluding men with prostate specific antigen greater than 4 ng/ml), only 1 of 382 transurethral resections of the prostate would identify clinically significant prostate cancer for a total of 390 in the American population in 3 years. Based on Medicare reported laser vaporization use a total of only 163 clinically significant cancers would be missed in more than 60,000 procedures. Conclusions: The incidence of T1a and T1b prostate cancer remains low and few patients have clinically significant prostate cancer. When prostate specific antigen screening is used, the number of clinically significant tumors missed by ablative procedures is low (average of 0.26{\%} of all procedures) and can be identified by prostate specific antigen screening.",
keywords = "laser therapy, prostate, prostate-specific antigen, prostatic neoplasms, transurethral resection of prostate",
author = "Meeks, {Joshua J.} and Maschino, {Alexandra C.} and McVary, {Kevin T.} and Sandhu, {Jaspreet S.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.juro.2012.08.093",
language = "English (US)",
volume = "189",
pages = "111--115",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

Clinically significant prostate cancer is rarely missed by ablative procedures of the prostate in men with prostate specific antigen less than 4 ng/ml. / Meeks, Joshua J.; Maschino, Alexandra C.; McVary, Kevin T.; Sandhu, Jaspreet S.

In: Journal of Urology, Vol. 189, No. 1, 01.01.2013, p. 111-115.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinically significant prostate cancer is rarely missed by ablative procedures of the prostate in men with prostate specific antigen less than 4 ng/ml

AU - Meeks, Joshua J.

AU - Maschino, Alexandra C.

AU - McVary, Kevin T.

AU - Sandhu, Jaspreet S.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Purpose: Laser vaporization of the prostate is widely used to treat lower urinary tract symptoms. It may decrease the hospital cost and morbidity associated with transurethral resection of the prostate. However, prostate cancer may go undetected because tissue is not taken at laser vaporization. To our knowledge the rate of clinically significant prostate cancer missed by laser vaporization has not been assessed to date. We determined the rate of clinically significant prostate cancer detected by transurethral resection of the prostate compared to the estimated number of cancers missed by laser vaporization. Materials and Methods: A total of 74,505 men diagnosed with stage T1 prostate cancer between 2004 and 2006 were identified from the SEER (Surveillance, Epidemiology and End Results) program in the United States. The total number of laser vaporizations and transurethral resections were calculated based on Medicare claims for the same period. Clinically significant cancer was defined as that with a Gleason score of 7 or greater in men 40 to 75 years old. Results: If prostate specific antigen screening were used uniformly (excluding men with prostate specific antigen greater than 4 ng/ml), only 1 of 382 transurethral resections of the prostate would identify clinically significant prostate cancer for a total of 390 in the American population in 3 years. Based on Medicare reported laser vaporization use a total of only 163 clinically significant cancers would be missed in more than 60,000 procedures. Conclusions: The incidence of T1a and T1b prostate cancer remains low and few patients have clinically significant prostate cancer. When prostate specific antigen screening is used, the number of clinically significant tumors missed by ablative procedures is low (average of 0.26% of all procedures) and can be identified by prostate specific antigen screening.

AB - Purpose: Laser vaporization of the prostate is widely used to treat lower urinary tract symptoms. It may decrease the hospital cost and morbidity associated with transurethral resection of the prostate. However, prostate cancer may go undetected because tissue is not taken at laser vaporization. To our knowledge the rate of clinically significant prostate cancer missed by laser vaporization has not been assessed to date. We determined the rate of clinically significant prostate cancer detected by transurethral resection of the prostate compared to the estimated number of cancers missed by laser vaporization. Materials and Methods: A total of 74,505 men diagnosed with stage T1 prostate cancer between 2004 and 2006 were identified from the SEER (Surveillance, Epidemiology and End Results) program in the United States. The total number of laser vaporizations and transurethral resections were calculated based on Medicare claims for the same period. Clinically significant cancer was defined as that with a Gleason score of 7 or greater in men 40 to 75 years old. Results: If prostate specific antigen screening were used uniformly (excluding men with prostate specific antigen greater than 4 ng/ml), only 1 of 382 transurethral resections of the prostate would identify clinically significant prostate cancer for a total of 390 in the American population in 3 years. Based on Medicare reported laser vaporization use a total of only 163 clinically significant cancers would be missed in more than 60,000 procedures. Conclusions: The incidence of T1a and T1b prostate cancer remains low and few patients have clinically significant prostate cancer. When prostate specific antigen screening is used, the number of clinically significant tumors missed by ablative procedures is low (average of 0.26% of all procedures) and can be identified by prostate specific antigen screening.

KW - laser therapy

KW - prostate

KW - prostate-specific antigen

KW - prostatic neoplasms

KW - transurethral resection of prostate

UR - http://www.scopus.com/inward/record.url?scp=84870956270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870956270&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2012.08.093

DO - 10.1016/j.juro.2012.08.093

M3 - Article

C2 - 23164392

AN - SCOPUS:84870956270

VL - 189

SP - 111

EP - 115

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -